The efficacy and safety of concurrent versus sequential chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis
- VernacularTitle:同步与序贯放化疗治疗局部晚期非小细胞肺癌有效性和安全性的系统评价与Meta分析
- Author:
Kai YANG
1
,
2
;
Li DOU
2
;
Wei CAO
1
,
2
;
Dacheng JIN
2
;
Qi WANG
1
,
2
;
Yunjiu GOU
2
Author Information
1. First Clinical Medical School, Gansu University of Chinese Medicine, Lanzhou, 730000, P. R. China
2. First Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
synchronous;
sequential;
chemoradiotherapy;
systematic review/meta-analysis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(12):1777-1785
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of concurrent chemoradiotherapy versus sequential chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer. Methods The relevant literature was searched in PubMed, Web of Science, CNKI and Wanfang databases from the inception to October 15, 2023, and the literature was screened according to the inclusion and exclusion criteria. Review Manager 5.3 software was used for meta-analysis of the literature, and the Cochrane bias risk assessment tool was used to evaluate the quality of the literature. Results Finally, 14 randomized controlled studies were included covering a total of 1048 patients. The results of meta-analysis showed that the overall response rate [OR=2.39, 95%CI (1.83, 3.11)], 1-year survival rate [OR=1.81, 95%CI (1.39, 2.35)], 2-year survival rate [OR=1.75, 95%CI (1.27, 2.42)] and 3-year survival rate [OR=2.33, 95%CI (1.49, 3.66)] were superior to sequential chemoradiotherapy (P<0.001). In terms of safety, concurrent chemoradiotherapy increased the incidence of radiation esophagitis (P<0.05), but there was no statistical difference in the incidence of leukopenia and radiation pneumonia (P>0.05). Conclusion For patients with locally advanced non-small cell lung cancer, the short-term efficacy of concurrent chemoradiotherapy is better than that of sequential chemoradiotherapy and can improve the 1-, 2- and 3-year survival rates, but the toxic side effects of the treatment are slightly greater than those of the sequential chemoradiotherapy.
